Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
Summary Background Early descriptions of patients admitted to hospital during the COVID-19 pandemic showed a lower prevalence of asthma and chronic obstructive pulmonary disease (COPD) than would be expected for an acute respiratory disease like COVID-19, leading to speculation that inhaled corticosteroi ds (ICSs) might protect against infection with severe acute respiratory syndrome coronavirus 2 or the development of serious sequelae. We assessed the association between ICS and COVID-19-related death among people with COPD or asthma using linked electronic health records (EHRs) in England, UK. Me thods In this obser...
Source: Current Awareness Service for Health (CASH) - September 30, 2020 Category: Consumer Health News Source Type: news

EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation
EMA's human medicines committee (CHMP) has completed its review of results from the RECOVERY study arm that involved the use of the corticosteroid medicine dexamethasone in the treatment of patients with COVID-19 admitted to hospital, and has concluded that dexamethasone can be considered a treatment option for patients who require oxygen therapy (from supplemental oxygen to mechanical ventilation). (Source: World Pharma News)
Source: World Pharma News - September 30, 2020 Category: Pharmaceuticals Tags: Featured EMA Regulatory Affairs Source Type: news

New peer reviews of COVID-19 preprints from the MIT Press journal Rapid Reviews: COVID-19
(The MIT Press) Peer reviewers highlight promising research highlighting reform in public health and employment law, an approach for identifying asymptomatic COVID-19 patients, and strong evidence that inhaled corticosteroids do not protect against COVID-19 related deaths. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 29, 2020 Category: Infectious Diseases Source Type: news

Serum Prednisolone and Corticosteroid Adherence in Asthma Serum Prednisolone and Corticosteroid Adherence in Asthma
Serum prednisolone measurements may be an effective means of monitoring adherence to oral corticosteroid treatment in severe asthma patients.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2020 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

What Are Systemic Disease Causes of Oral Ulcers?
Discussion Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range. Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support. Objective To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. Design, Setting, and Participants Prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The trials were con...
Source: Current Awareness Service for Health (CASH) - September 17, 2020 Category: Consumer Health News Source Type: news

Skin lightening creams may increase risk of adrenal insufficiency
Women who misuse corticosteroid creams for cosmetic skin lightening may be at risk of developing adrenal insufficiency, according to research presented at the European Society of Endocrinology’s digital Congress, e-ECE 2020.Times Now News (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 11, 2020 Category: Endocrinology Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Media News - September 10, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Investor Update - September 10, 2020 Category: Pharmaceuticals Source Type: news

Corticosteroids in the treatment of suspected or confirmed COVID-19 , Chief Medical Officer
Following recent publication of the REMAP-CAP trial for hydrocortisone and a meta-analysis of corticosteroids, the WHO has recently issued new interim guidance recommending the use of systemic corticosteroids in severe and critical COVID-19 disease. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 4, 2020 Category: Consumer Health News Source Type: news

Update: publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older), Chief Medical Officer (updated 3rd September 2020)
This alert replaces the most recent Remdesivir alert CEM/CMO/2020/028 which was issued on 03 July. It has been updated (on page 2) to reflect the publication of revised World Health Organisation guidance on the use of corticosteroids in the treatment of COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 4, 2020 Category: Consumer Health News Source Type: news

Baricitinib in Moderate-to-Severe Atopic Dermatitis Baricitinib in Moderate-to-Severe Atopic Dermatitis
Baricitinib may provide another treatment option for patients with atopic dermatitis who did not adequately respond to corticosteroid therapy.The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 4, 2020 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

UPMC, Pitt on front lines of global work to speed Covid-19 treatment
It's one thing to have a single study that suggests that a treatment could be helpful. It's another thing, like researchers have now for corticosteroids, multiple studies in hand. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 3, 2020 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Steroid Drugs Are an Effective Treatment for Severe COVID-19: WHO
A meta-analysis of seven randomized controlled trials concludes that dexamethasone and other corticosteroids reduce 28-day mortality in seriously ill patients. (Source: The Scientist)
Source: The Scientist - September 3, 2020 Category: Science Tags: News & Opinion Source Type: news

Critical care in adults [NG159], NICE (updated 3rd September 2020)
The purpose of this guideline is to maximise the safety of patients who need critical care during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources. On 3 September 2020, we added guidance on treatment with corticosteroids for people with severe or critical COVID-19, in line with our 2 External 0 0 0 prescribing briefing on corticosteroids false https://www.nice.org.uk/guidance/ng159/resources/covid19-prescribing-briefing-corticosteroids-pdf-8839913581 true false%>. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 3, 2020 Category: Consumer Health News Source Type: news

Analysis of seven trials finds that corticosteroids reduce risk of death by 20 per cent in critically ill COVID-19 patients
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - September 3, 2020 Category: Hospital Management Tags: Hospital News Source Type: news

Affordable Steroids Could Reduce Some COVID-19 Deaths by One-Third, Says World Health Organization
:rockYou’d think a robust immune system would be an awfully good thing to have if you’re battling COVID-19—and much of the time it is. But in the most extreme cases—the ones the World Health Organization (WHO) labels as “severe and critical,” denoting the most extremely ill, typically hospitalized patients, with the highest risk of death—the system meant to protect the body from disease can make things worse, leading to inflammation and other damage to the lungs, which in turn can result in an often fatal case of acute respiratory distress syndrome (ARDS). In June, a single large s...
Source: TIME: Health - September 2, 2020 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news

Multiple Studies Find Steroids Fight Severe COVID
The data showed that the use of corticosteroids in the care of these patients cut the death rate (after one month of treatment) by about one-third. (Source: WebMD Health)
Source: WebMD Health - September 2, 2020 Category: Consumer Health News Source Type: news

Steroids Boost COVID-19 Survival Rates Among Those Critically Ill: Study
The analysis from seven international trials has prompted the WHO to recommend corticosteroid drugs for patients with severe and critical COVID-19. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - September 2, 2020 Category: Science Source Type: news

Dexamethasone, other corticosteroids help hospitalized COVID-19 patients, research finds
The corticosteroid dexamethasone reduces the need for ventilator support in patients hospitalized with COVID-19, according to a study published Wednesday by JAMA. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 2, 2020 Category: Consumer Health News Source Type: news

New studies reinforce evidence that corticosteroids improve survival rates among critically ill COVID-19 patients, NIHR
Four papers published today on the use of corticosteroids to treat COVID-19 have reinforced evidence that outcomes for severely affected patients can be significantly improved by using these inexpensive and widely available drugs, with one paper suggesting the risk of death can be reduced by up to 20%. The papers - simultaneously published in the Journal of the American Medical Association (JAMA) - include findings from the REMAP-CAP study being conducted across 15 countries, around the world and for which the NIHR's Clinical Research Network and partner research institutes from devolved nations recruited close to 71% of a...
Source: Current Awareness Service for Health (CASH) - September 2, 2020 Category: Consumer Health News Source Type: news

Steroids cut death rates among critically ill COVID-19 patients, studies suggest
Treating critically ill COVID-19 patients with corticosteroid drugs reduces the risk of death by 20 per cent, an analysis of seven international trials found on Wednesday, prompting the World Health Organization to update its advice on treatment. (Source: CBC | Health)
Source: CBC | Health - September 2, 2020 Category: Consumer Health News Tags: News/Health Source Type: news

Analysis of seven trials finds that corticosteroids reduce risk of death by 20 per cent in critically ill COVID-19 patients
Corticosteroids reduce the risk of death among critically ill COVID-19 patients by 20 per cent, an analysis of seven trials published today [2 September] in the Journal of the American Medical Association (JAMA) has found. The results of three of the trials included in the meta-analysis are also published in JAMA today. (Source: University of Bristol news)
Source: University of Bristol news - September 2, 2020 Category: Universities & Medical Training Tags: Health, Research, International; Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences; Press Release Source Type: news

Multiple Studies Confirm Steroids Can Fight Severe COVID-19
WEDNESDAY, Sept. 2, 2020 -- A slew of " gold standard " clinical trials offer new hope for patients battling severe COVID-19: cheap, common drugs known as corticosteroids appear to cut the death rate by a third. Publication of new data on treatment... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 2, 2020 Category: General Medicine Source Type: news

Association between treatment with corticosteroids, risk of death among critically ill patients with COVID-19
(JAMA Network) The results of seven randomized clinical trials with 1,703 critically ill patients with COVID-19 were combined to estimate the association between administration of corticosteroids compared with usual care or placebo and the risk of death after 28 days. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 2, 2020 Category: Infectious Diseases Source Type: news

Corticosteroids improve survival in critically ill COVID-19 patients
(University of Pittsburgh) In a tremendous demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in eight countries to find that inexpensive, widely available steroids improve the odds that very sick COVID-19 patients will survive the illness. The findings were made through the " Randomized Embedded Multifactorial Adaptive Platform-Community Acquired Pneumonia " (REMAP-CAP) trial and are reported today in JAMA as part of a four-article package. The World Health Organization is updating its COVID-19 treatment guidance as a result. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 2, 2020 Category: Infectious Diseases Source Type: news

No Extra Risk of Psychiatric Events Seen With Montelukast No Extra Risk of Psychiatric Events Seen With Montelukast
A new study failed to find an increased risk of psychiatric adverse events in asthma patients taking montelukast compared with patients who use inhaled corticosteroids.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 1, 2020 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

Corticosteroids Appear to Stop Abnormalities in Kawasaki Disease Corticosteroids Appear to Stop Abnormalities in Kawasaki Disease
Addition of corticosteroids to initial intravenous immunoglobulin treatment appears to reduce the rate of coronary-artery abnormalities in high-risk patients with Kawasaki disease.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 21, 2020 Category: Radiology Tags: Cardiology News Source Type: news

Combination Therapy May Benefit Some With Kawasaki Disease
WEDNESDAY, Aug. 19, 2020 -- Adding corticosteroids to initial intravenous immunoglobulin seems beneficial for preventing coronary artery abnormalities in high-risk patients with Kawasaki disease (KD), according to a study published online Aug. 19 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2020 Category: Pharmaceuticals Source Type: news

Combo therapy may prevent blood vessel complications in children with Kawasaki disease
(American Heart Association) For children with Kawasaki disease with higher risk of developing blood vessel complications, adding corticosteroids to standard intravenous immunoglobulin treatment could boost initial treatment response and prevent complications.Researchers used real-world data from large, nationwide Japanese Kawasaki disease surveys to compare combination therapy with the standard treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 19, 2020 Category: International Medicine & Public Health Source Type: news

Psoriasis Guidelines Focus on Treatment of Adults Psoriasis Guidelines Focus on Treatment of Adults
The guidelines noted the'key role'of topical corticosteroids in treating psoriasis'especially for localized disease. 'Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 10, 2020 Category: Dermatology Tags: Dermatology News Source Type: news

Janssen Announces U.S. FDA Approval of SPRAVATO ® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
TITUSVILLE, N.J. – (August 3, 2020) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation orbehavior.1 SPRAVATO® is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours,1 providing a new option for significant symptom relief until a longer-te...
Source: Johnson and Johnson - August 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Reducing corticosteroid use in rheumatoid arthritis
(Charit é - Universit ä tsmedizin Berlin) Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects? How can these drugs be discontinued without giving rise to glucocorticoid withdrawal syndrome? These were the questions addressed by the SEMIRA study, a large European trial led by Charit é - Universit ä tsmedizin Berlin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 31, 2020 Category: International Medicine & Public Health Source Type: news

No Fracture Risk in Children With AD Who Use Topical Steroids No Fracture Risk in Children With AD Who Use Topical Steroids
' Little has been published about the risk of fracture in children with atopic dermatitis on topical corticosteroids specifically,'one of the study authors, Reese L. Imhof, said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news

Triple-Therapy Combo Decreases COPD Exacerbations Triple-Therapy Combo Decreases COPD Exacerbations
The combination of an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2 agonist improves control of COPD exacerbations, findings from a phase 3 trial show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

A dual antenatal therapy benefits extreme preterm babies better than either alone or none
(University of Alabama at Birmingham) Researchers, led by Samuel Gentle, MD, assistant professor of pediatrics in the University of Alabama at Birmingham School of Medicine, report that antenatal treatment with both magnesium sulfate and corticosteroids together yields an increased benefit for children born at 22 to 26 weeks of gestation, compared to no antenatal treatment or with either therapy alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2020 Category: International Medicine & Public Health Source Type: news

Use of corticosteroids in asthma and COPD patients with or without COVID-19
This article provides a critical review of clinical evidence and offers a detailed discussion on their safety and efficacy of corticosteroids. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 10, 2020 Category: Consumer Health News Source Type: news

Oral Corticosteroid Bursts Carry Risk for Severe Adverse Events
Highest rates of adverse events seen within first month after initiating short course of oral steroids (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 7, 2020 Category: Respiratory Medicine Tags: Cardiology, Dermatology, Family Medicine, Gastroenterology, Internal Medicine, Allergy, Emergency Medicine, Pharmacy, Pulmonology, Rheumatology, Journal, Source Type: news

Oral Corticosteroid Bursts Carry Risk for Severe Adverse Events
TUESDAY, July 7, 2020 -- Prescriptions for oral steroid bursts are associated with a 1.8- to 2.4-fold increased risk for severe adverse events within the first month after initiation of drug therapy, according to a study published online July 7 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 7, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders [NG167], NICE (updated 2nd July 2020)
Latest updates. 2 July 2020 We added a bullet point to recommendation 3.2 to highlight the possible risk of adrenal crisis for patients on long-term corticosteroids. 21 May 2020 We added a link from recommendation 3.2 to the advice in NICE's COVID-19 rapid guideline: children and young people who are immunocompromised on factors to take into account when considering temporarily stopping some drugs. We aligned recommendation 1.4 with current government advice on social distancing. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 3, 2020 Category: Consumer Health News Source Type: news

Corticosteroids in the Treatment of Sepsis
The review summarized here by Annane et al found that corticosteroids may confer a short-term, but not overall, mortality benefit for patients with sepsis. Specifically, they found moderate certainty evidence for reduced 28-day mortality (relative risk [RR] 0.91, 95% confidence interval [CI] 0.84 to 0.99; n=11233). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 1, 2020 Category: Consumer Health News Source Type: news

Patients With Pulmonary Disease Shouldn't Quit Aerosolized Medication Over COVID Fears Patients With Pulmonary Disease Shouldn't Quit Aerosolized Medication Over COVID Fears
COVID-19 concerns should not stop patients from using inhaled corticosteroids, a new commentary article suggests.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 1, 2020 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

Asthma Seems Not to Be Linked to COVID - 19 Hospitalization
No increased risk seen for hospitalization with ongoing use of inhaled corticosteroids (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nursing, Pulmonology, Journal, Source Type: news

Inhaled corticosteroids: A rapid review of the evidence for treatment or prevention of COVID-19, CEBM
This review aimed to synthesise the current literature on the role of inhaled corticosteroids in moderating the disease course or severity of COVID-19 disease. Inhaled ciclesonide has been shown to suppress SARS-CoV-2 replication in cultured cells and it is suggested that it exhibits direct acting anti-viral activity in addition to its intrinsic anti-inflammatory function. Inhaled ciclesonide has therefore been proposed as a candidate drug for treatment of patients suffering Covid19. However, further in vitro research is required to investigate whether this finding is replicable. Furthermore, at the time of writing, there ...
Source: Current Awareness Service for Health (CASH) - June 23, 2020 Category: Consumer Health News Source Type: news

Jun 19, 2020 This Week in Cardiology Podcast Jun 19, 2020 This Week in Cardiology Podcast
COVID19, corticosteroids, CAC, SGLT2i, and vericiguat are the topics discussed by Dr. John Mandrola in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 20, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Management of patients with musculoskeletal and rheumatic conditions on corticosteroids, NHS England
This supersedes the specialist guidance “Management of Patients with Musculoskeletal and Rheumatic Conditions on Corticosteroids” published as part of the NHS England and Improvement phase 1 response to the coronavirus pandemic. It relates to musculoskeletal (MSK) service provision across primary, community and secondary care and is a pplicable to adults and children. The use of steroid medication is one of the management options for a range of musculoskeletal conditions and in particular rheumatic conditions, and this guidance aims to assist decisions on the use of such medication during the pandemic. (Source:...
Source: Current Awareness Service for Health (CASH) - June 17, 2020 Category: Consumer Health News Source Type: news

Africa: WHO Welcomes Preliminary Results about Dexamethasone Use in Treating Critically Ill COVID-19 Patients
[WHO] Geneva -The World Health Organization (WHO) welcomes the initial clinical trial results from the United Kingdom (UK) that show dexamethasone, a corticosteroid, can be lifesaving for patients who are critically ill with COVID-19. For patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth, according to preliminary findings shared with WHO. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - June 17, 2020 Category: African Health Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Assessment and management of adults with asthma during the covid-19 pandemic, BMJ
Review states in those with symptoms of acute asthma, corticosteroids can and should be used if indicated and not withheld on the basis of suspected COVID-19 as a trigger. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 10, 2020 Category: Consumer Health News Source Type: news

Controversy Remains Over Corticosteroids in COVID-19 Controversy Remains Over Corticosteroids in COVID-19
The most commonly invoked rationale for giving steroids in patients with severe COVID-19 is to modulate the destructive inflammatory immune response that occurs with advancing disease.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - June 1, 2020 Category: Emergency Medicine Tags: Critical Care News Source Type: news